Source: International Congress 2016 – IPF: from pathogenesis to treatment I



Rating:

Share or cite this content

Citations should be made in the following way:
Thomas Hewson (Nottingham, United Kingdom), Thomas Hewson, Tricia McKeever, Jack Gibson, Richard Hubbard, John Hutchinson. Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study. Eur Respir J 2016; 48: Suppl. 60, 788

Member's Comments

No comment yet.

Related content which might interest you: Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease Source: International Congress 2014 – Sarcoidosis Year: 2014 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study Source: Eur Respir J 2007; 30: Suppl. 51, 119s Year: 2007 Tuberculosis in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015